News

PEP-Therapy is recruiting a R&D trainee to support the development of PEP-010.

Check out the internship offer and do not hesitate to apply.

We are pleased to announce the publication of a paper highlighting our translational study in Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease, showing that our lead product, PEP-010, induces apoptosis in cancer cells, which can be monitored by pharmacodynamic biomarkers.

The paper is available in Open Access, DOI 10.1016/j.bbadis.2024.167492.

We are thrilled to announce the publication of our work in Frontiers in Pharmacology, showing that our lead product, PEP-010, is effective in monotherapy and in combination with paclitaxel in resistant ovarian adenocarcinoma.

The paper is available in Open Access, DOI 10.3389/fphar.2024.1444973.

PEP-Therapy is recruiting a Regulatory Affairs & Market Access Officer to support the development of PEP-010.

Check out the job offer and do not hesitate to apply.

We are happy to share updates on our PEP-010 program at the EACR Annual Meeting which will be held June 10-13 in Rotterdam, Netherlands. Come and visit our posters!

Title Poster 1: PP2A triggers the cell death signaling cascade after treatment with PEP-010, a first-in-class clinical-stage pro-apoptotic peptide.

Abstract Number: 0252

Session: Experimental/Molecular Therapeutics, Pharmacogenomics

Title Poster 2: PEP-010, a first-in-class clinical-stage pro-apoptotic peptide is efficient in vitro and in ovo on pancreatic cancer in monotherapy and in combination with different chemotherapies.

Abstract Number: 0302

Session: Translational Research

Session Date and Time: June 11, 2024, 11:00 AM – 8:15 PM

Venue: Rotterdam Ahoy, Rotterdam, Netherlands, Poster and Exhibition Hall

PEP-Therapy appoints Hatem Azim, MD, PhD, as Chief Medical Officer.

Hatem brings over 20 years of experience in early to late-stage oncology clinical development in top tier biotech companies.

PEP-Therapy and Institut Curie announce first patients dosed in Phase Ib clinical trial evaluating PEP-010 in ovarian and pancreatic cancers.

We are happy to announce that we will present the results from the Phase Ia on PEP-010 at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics which will be held October 11-15 in Boston, MA. Come and visit our poster!

Title: A first-in-human Phase 1a/b of PEP-010, a proapoptotic bifunctional peptide, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer: results from the dose escalation study

Poster Number: B046

Session: Poster Session

Session Date and Time: Friday, October 13 | 12:30 pm – 4:00 pm ET

Session location: Level 2, Exhibit Hall D

We are happy to share updates on our PEP-010 program at the AACR Annual Meeting which will be held April 14-19 in Orlando, FL. Come and visit our poster!

Title: The proapoptotic peptide PEP-010 is efficient on several models of different tumor origins and it can be monitored by pharmacodynamic biomarker candidates in clinical practice.

Abstract Number: 6129

Session: Apoptosis and Growth Factor Receptors as Therapeutic Targets

Session Date and Time: April 19, 2023, 9:00 AM – 12:30 PM

Venue: Orange County Convention Center, Orlando, Florida, Poster Section 15

Our abstract has been selected as a poster presentation for the AACR Annual Meeting 2023 and is now available in Cancer Research:

“The proapoptotic peptide PEP-010 is efficient on several models of different tumor origins and it can be monitored by pharmacodynamic biomarker candidates in clinical practice”

PEP-Therapy welcomes Ursula Vogel to its Board of Directors.

PEP-Therapy and Institut Curie announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors.

PEP-Therapy extends Series-A financing, raising a total of €5.4 million to progress the clinical development of its lead candidate, PEP-010.

PEP-Therapy raises €2.75 million in Series A financing to advance its lead drug candidate in oncology, PEP-010, into clinical trials.

PEP-Therapy and Institut Curie granted approval from the French National Agency for Medicines and Health Products (ANSM) to start first-in-human clinical trial of PEP-Therapy’s lead drug candidate, PEP-010 for the treatment of advanced solid tumors.

PEP-Therapy announces the appointments in its Scientific Advisory Board (SAB) of four experts in oncology and peptide development: Pr. Isabelle Ray-Coquard, MD, PhD; Pr. Mario Campone, MD, PhD; Pr. Jean Martinez, PhD, and Dr. Bruno Giroux, MD, PharmD.

PEP-Therapy is proud to be part of the laureates of ReAliZe, the open innovation program of AstraZeneca in oncology.

PEP-Therapy announces that its first-in-class drug candidate, PEP-010, successfully completed Good Laboratory Practice (GLP) toxicity study, moving towards its first-in-human clinical trial.

PEP-Therapy, Institut Curie and Gustave Roussy join together to conduct the Clever-Peptide project.

It aims at the development of an innovative anti-cancer peptide, firstly for the treatment of triple-negative breast cancer, and its companion biomarker, predictive of treatment efficacy. Approved by the Medicen Paris Region cluster, this collaborative project obtains 2,9 M€ funding.

PEP-Therapy announces the presentation of preclinical data on the PEP-010 drug candidate at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place from April 14 to 18 in Chicago, USA.

PEP-Therapy raises €1.2 million.

The company continues the development of its portfolio of drug candidates and of their companion biomarkers in oncology.

PEP-Therapy took part in the 3rd edition of the MEET2WIN business convention organized by MATWIN in Bordeaux on May 11th and 12th, dedicated to open innovation, collaborative research and technology transfer in oncology.

PEP-Therapy was awarded a prize as one of the 2 best pitch presentations.

PEP-Therapy was proud to take part in “The Investment Plan for Europe: delivering results” seminar at the European Commission on November 29th.

One major pillar of the Plan is the European Fund for Strategic Investments (EFSI).

PEP-Therapy is one of the approved EFSI project. The company received €1 million support from Quadrivium 1, a French investment fund that received a €20 million injection from the European Investment Fund (EIF).

Both partners are featured in the Investment plan for Europe summary document.

PEP-Therapy took part in the 3rd edition of the MedStartUp days at the Alexandria Center For Life Science in New York.

MedStartUp, organized by the Galien Foundation and Business France, bring together highly innovative French companies in the healthcare industry and American leaders in the pharma, medtech and digital health industries, to encourage and reward new transatlantic partnerships.

PEP-Therapy and partners have been awarded a European H2020 grant to fight eye cancer for the next 5 years.

Under the coordination of Institut Curie, UM Cure 2020 is a new European consortium involving 12 partners to foster research on metastatic uveal melanoma (UM), a rare disease.

UM Cure 2020 has received €6 million of funding to develop new therapeutic approaches to treat metastatic UM.

PEP-Therapy is ranked among the French 100 top start-ups to invest in by Challenges business magazine.

A few days later, Challenges provides a portrait of PEP-Therapy.

The finalists presented their venture at the 2015 Science|Business annual summit in Barcelona, where leaders from research, industry and policy have debated how best unleash Europe’s technological potential.

PEP-Therapy is very pleased to be profiled in this week BioCentury issue.

The company is undertaking development of its first drug candidate and its companion diagnostic in oncology.

BiotechFinances is talking about it here.